Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Sold by Prudential Financial Inc.

Prudential Financial Inc. trimmed its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 20.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 96,817 shares of the company’s stock after selling 25,273 shares during the quarter. Prudential Financial Inc. owned approximately 0.15% of Kymera Therapeutics worth $3,895,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of KYMR. Blue Trust Inc. raised its stake in Kymera Therapeutics by 74.8% in the fourth quarter. Blue Trust Inc. now owns 631 shares of the company’s stock valued at $25,000 after buying an additional 270 shares in the last quarter. Harbor Capital Advisors Inc. increased its holdings in shares of Kymera Therapeutics by 1.7% in the 4th quarter. Harbor Capital Advisors Inc. now owns 40,987 shares of the company’s stock valued at $1,649,000 after acquiring an additional 684 shares during the last quarter. KBC Group NV raised its position in shares of Kymera Therapeutics by 53.8% during the 4th quarter. KBC Group NV now owns 2,151 shares of the company’s stock worth $87,000 after acquiring an additional 752 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Kymera Therapeutics by 8.8% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,289 shares of the company’s stock worth $534,000 after purchasing an additional 915 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in Kymera Therapeutics by 10.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,733 shares of the company’s stock valued at $552,000 after purchasing an additional 1,311 shares in the last quarter.

Insider Activity at Kymera Therapeutics

In other Kymera Therapeutics news, COO Jeremy G. Chadwick sold 1,383 shares of the firm’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $42,112.35. Following the completion of the sale, the chief operating officer now owns 67,800 shares of the company’s stock, valued at approximately $2,064,510. This trade represents a 2.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Bruce N. Jacobs sold 7,035 shares of the business’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $214,215.75. Following the sale, the chief financial officer now owns 201,886 shares in the company, valued at $6,147,428.70. The trade was a 3.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 13,788 shares of company stock worth $455,202 over the last three months. 15.82% of the stock is currently owned by corporate insiders.

Kymera Therapeutics Stock Performance

KYMR stock opened at $25.24 on Wednesday. Kymera Therapeutics, Inc. has a one year low of $24.36 and a one year high of $53.27. The company has a fifty day moving average of $35.23 and a 200-day moving average of $41.48. The stock has a market capitalization of $1.64 billion, a PE ratio of -10.79 and a beta of 2.22.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.12). Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The business had revenue of $7.39 million during the quarter, compared to analysts’ expectations of $14.81 million. Equities analysts forecast that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on KYMR. Leerink Partners reissued an “outperform” rating and set a $60.00 price objective on shares of Kymera Therapeutics in a report on Friday, December 27th. Stephens reissued an “overweight” rating and issued a $60.00 price target on shares of Kymera Therapeutics in a research report on Tuesday, January 21st. HC Wainwright raised their price objective on Kymera Therapeutics from $54.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Citigroup started coverage on Kymera Therapeutics in a research report on Thursday, March 13th. They set a “buy” rating and a $52.00 target price on the stock. Finally, BTIG Research started coverage on Kymera Therapeutics in a research note on Tuesday, December 10th. They set a “buy” rating and a $60.00 price target on the stock. Three analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Kymera Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $56.36.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.